Indivior Reports Third Quarter 2026 Financial Results

Indivior reported Q3'26 revenue of $356 million, up 13% year over year, including record SUBLOCADE revenue of $267 million, up 22%. Net income reached a record $137 million and adjusted EBITDA a record $211 million, up 76%, with margins expanding year over year. The company said it remains on track to close its merger with Supernus on November 2.

Analysis

The key signal is not simply product growth, but the widening gap between revenue growth and reported profit growth. If the margin expansion reflects durable mix and cost leverage, forward earnings power may be underappreciated; if it reflects discrete items or accounting effects, extrapolating the quarter risks a sharp reset. Reconcile adjusted EBITDA to cash flow, acquisition/integration costs, and the full-year outlook before underwriting a new run-rate.

The November 2 Supernus close is the near-term event: it may shift INDV’s valuation from a relatively focused Sublocade growth story to a combined-company execution and capital-allocation story. Transaction terms, financing, and any closing conditions are not provided here, so avoid assuming either accretion or dilution. Over 1–3 months, integration costs and the first combined-company guidance matter more than the headline close; over 6–18 months, sustained Sublocade uptake and diversification beyond that franchise determine whether the market awards a durable growth multiple. Competition from Braeburn’s Brixadi and payer access are relevant checks on growth quality. A pullback in product demand or weaker reimbursement could quickly expose the concentration risk.

Key Decisions for Investors

• Do not chase the earnings headline ahead of the merger close without checking consideration/exchange terms, financing, closing conditions, and post-close share count; these determine what INDV holders actually own.
• After closing, consider a staged long only if management supports the margin step-up with cash conversion and forward guidance. Falsify the thesis if guidance retreats, adjusted EBITDA fails to convert into operating cash, or Sublocade growth/access weakens.
• Set an alert for the first combined-company update: track integration expense, leverage/capital allocation, and product-level guidance. Treat any claim of durable synergies as unproven until reflected in cash flow.
• No high-conviction pair or options trade from this release alone: valuation, transaction economics, and the drivers of the unusually large margin change are missing.